The regulatory body of Switzerland, SwissMedic, has just approved an anti-cancer drug indicated for the treatment of metastatic pancreatic and breast cancer. Abraxane (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) is a product of Celgene Corporation, a New Jersey-based biotechnology company that develops pharmaceutical treatments for cancer and inflammatory diseases. At present, the drug has received approval in over 30 countries as a treatment for metastatic pancreatic cancer, and in over 40 for the treatment of metastatic breast cancer.

Today, research into therapeutic solutions for treating metastatic breast cancer (MBC) or Stage IV breast cancer is still rare. Researchers normally begin studying patients in later stages of the disease, but tend to shift their focus to early and preventive solutions once enough data on safety and tolerance has been gathered, leaving limited progress on treating MBC. This new approval in Switzerland, however, is oriented toward treating both pancreatic and breast cancer in advanced stages, showing that SwissMed